CSPG4 and melanoma: Chondroitin-sulfate proteoglycan 4 (CSPG4), also known as neuronal-glial antigen 2 (NG2), is considered a promising candidate target for cancer immunotherapy because of its diffuse and high level expression in a broad range of tumor types, such as melanoma, glioblastoma and subsets of breast carcinomas.25